p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer
Status:
Completed
Trial end date:
2018-04-23
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and recommended dose of the combination of p53MVA
vaccine (modified vaccinia virus ankara vaccine expressing tumor protein p53 [p53]) and
gemcitabine hydrochloride in treating patients with ovarian epithelial cancer that has come
back. Vaccines made from inserting a laboratory-treated gene into a person's tumor cells may
help the body build an effective immune response to kill tumor cells that express p53. Drugs
used in chemotherapy, such as gemcitabine hydrochloride, work in different ways to stop the
growth of tumor cells, either by killing the cells, by stopping them from dividing, or by
stopping them from spreading. Giving modified vaccinia virus ankara vaccine expressing p53
together with gemcitabine hydrochloride may work better in treating patients with ovarian
epithelial cancer.